Mutant KRAS is a druggable target for pancreatic cancer

Elina Zorde Khvalevsky, Racheli Gabai, Itzhak Haim Rachmut, Elad Horwitz, Zivia Brunschwig, Ariel Orbach, Adva Shemi, Talia Golan, Eylon Yavin, Hilla Giladi, Ludmila Rivkin, Alina Simerzin, Rami Eliakim, Abed Khalaileh, Ayala Hubert, Maor Lahav, Yael Kopelman, Eran Goldin, Alan Dancour, Yael HantsSagit Arbel-Alon, Rinat Abramovitch, Amotz Shemi, Eithan Galun

Tel Aviv University, The Hebrew University of Jerusalem

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Mutant KRAS is a druggable target for pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences